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Abstract: Recently, serum free light chain (FLC) assays 
incorporating anti-kappa (κ) and anti-lambda (λ) FLC 
monoclonal antibodies have become available: N Latex 
FLC assay (Siemens) and Seralite® (Abingdon Health). The 
purpose of this review is to provide an overview of these 
two new monoclonal antibody-based methods. In doing 
so, the review will outline the performance characteris-
tics of each method, including a summary of: assay prin-
ciples, antibody specificity, analytical performance and 
assay performance in disease. Additionally, the review 
will describe the potential user benefits of adopting these 
new generation FLC assays, which are designed to over-
come the established limitations of existing polyclonal 
antibody based FLC assays.
Keywords: free light chains; myeloma; point of care; 
turbidimetry.
Introduction
The key components for any kappa (κ) and lambda (λ) free 
light chain (FLC) assay are the detection antibodies. These 
antibodies ultimately determine the performance charac-
teristics of the assay in which they are incorporated. To 
be defined as effective antibodies, several factors must be 
considered.
Firstly, the antibodies can be either monoclonal or pol-
yclonal. The use of monoclonal antibodies (mAbs) results 
in higher lot-to-lot consistencies in assay performances, 
and does not need renewed immunization, purification 
and processing to obtain specificity, as required for poly-
clonal antibodies. Clearly, a substantial benefit of reduced 
batch variation is the potential for more reliable patient 
monitoring, particularly when tracking patients through 
disease therapy and remission. Furthermore, most mAbs 
can be selected to have higher affinities than polyclonal 
antibodies and have better defined specificities, thus 
avoiding cross-reactivity with other proteins, including 
immunoglobulin bound-light chains (LC).
Both κLC and λLC are, by nature, highly heterogene-
ous molecules. The protein sequences show high vari-
ability in the antigen-binding domains. The constant (i.e. 
invariable domains) of the LC proteins are coded by only 
one gene for κ and up to seven genes for λ and therefore 
may serve as the best target for mAb binding to ensure full 
and consistent recognition of these proteins [1, 2]. Besides 
binding to the preserved sequences of the LC proteins, 
mAbs should bind to the exposed part of the LC protein 
that is hidden when LC is bound to immunoglobulin 
heavy chains.
Several studies have described the production of mAbs 
to FLCs that fulfill at least the criterion of binding to free 
and not to heavy chain-bound LC [2–5]. Using these mAbs, 
several assays have been developed, but not all of these 
tests have subsequently become commercially available.
In this review, two commercial methods are described 
which demonstrate that use of mAbs for the detection of 
FLC in serum is comparable with polyclonal-based assays 
for patient diagnosis and monitoring, and have the pre-
dicted analytical performance benefits of mAb-based 
assays. The N Latex FLC assays are nephelometric assays 
for the Siemens BN™-systems and the Seralite® assay is a 
rapid, lateral flow test.
The N Latex FLC κ and λ assays
Assay principle
The N Latex FLC assays (Siemens Healthcare Diagnos-
tic Products GmbH, Marburg, Germany) are latex-based 
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nephelometric assays for the measurement of κ and λFLC 
in serum, Li-heparin plasma, EDTA plasma, urine and cer-
ebrospinal fluid [5]. The assays are specifically designed 
for the Siemens BN™ systems. For the assays, panels of 
specific murine mAbs to either κ or λFLC are covalently 
coupled to latex beads. With the use of more than one mAb 
in the assay, detection of all variations of LC proteins is 
supported. The latex beads ensure the needed sensitivity 
and reduce, together with the high affinity antibodies, the 
reaction time of the assays. Additionally, a strong deter-
gent dissociates the sticky FLC molecules from hydropho-
bic surfaces and ensures recognition by the antibodies. 
Both FLC assays contain a short pre-reaction and a 10 min 
main reaction. The pre-reaction protects the reaction from 
antigen excess and prevents false negative results. The 
short pre-reaction is only possible with the use of high 
affinity antibodies. The pre-reaction starts immediately 
when a small amount of sample is added to the reaction 
cuvette and should give sufficient agglutination within 
the given pre-reaction time. During the agglutination reac-
tion, non-specific reactions are prevented with the use of 
mouse immunoglobulins and strong detergents.
FLC antibody specificity
For the development of the FLC assays, panels of more 
than 150 monoclonal mouse antibodies were created. For 
this, mice were immunized with polyclonal human κ and 
λ from multiple donors. The mAbs were selected based 
on specificity in an ELISA system as previously described 
[5]. During the selection procedure more than 90% of the 
mAbs were found to be specific for the free κ and λ mol-
ecules and non-responsive to intact immunoglobulins. 
After cross matching, non-competing mAbs were tested 
on purified monoclonal and polyclonal κ and λFLC. The 
non-competing mAbs should recognize all allotypes of 
κFLC and isotypes of λFLC. The selected mAbs proved 
responsive to monoclonal and polyclonal FLC. In the next 
step the mAbs were covalently bound to latex beads and 
tested in the nephelometer. Once the final assay protocols 
on the BN™ systems were established, over 2150 clinical 
samples were tested for κFLC and λFLC in serum and com-
pared to the Freelite® assays (Figure 1A and B) (unpub-
lished data). There is a clear numerical difference between 
the methods especially for λFLC. With low and very high 
concentrations of FLC, the methods gave results which 
may differ more than 10-fold. At low concentrations, these 
differences are partially explained by ‘the gap effect’ in 
the Freelite® assays (for explanation see further on). This 
inaccuracy in the Freelite® assays strongly influences the 
ratio of involved/ uninvolved light chains. In Figure  1C, 
the direct comparison of the κFLC/λFLC ratio for both 
methods is shown. The overall identity for ratios identi-
fied as low, normal or increased was 86% with a Cohen’s 
κ of 0.77. Within the reference ranges for the ratios, both 
methods show good similarity, while outside these ranges 
the ratios may show greater differences.
The constant domains of the light chains, as indi-
cated by the name, are well preserved, but also contain a 
limited number of allotypes or isotypes [1]. The selected 
mAbs for the panels reacted with the constant domain 
of the light chains. The phenotype of monoclonal κ and 
λFLC may differ by a yet unknown mechanism and lead 
to substantial variations in the structure of the light chain 
molecule. Monoclonal κ and λFLC come in different 
shapes and sizes when the molecules multimerize [6–9]. 
The formation of these multimers may hamper or enhance 
recognition by the antibodies. The outcome of the meas-
urement is based on the availability of the epitopes in the 
light chain molecule, more than the genetic variations in 
the constant domain of the FLC. Different sets of mAbs 
may therefore lead to different results, as shown during 
the development of the mAbs used in the Seralite® assay 
[2]. The spearman correlation between the results of dif-
ferent combinations of mAbs for λ was 0.97, but for κ the 
correlation was 0.78.
Analytical performance
The major advantages of the use of mAbs in the assays 
are the reduced variability between the lots, and the high 
affinity binding to the LC molecules. The lot-to-lot con-
sistency of the assays was demonstrated to be 7.3% for 
κFLC and 10% for λFLC [5, 10, 11]. Pretorius et al. [10] and 
Lock et  al. [11] tested only a limited number of lots, but 
when samples were measured on more combinations of 
calibrators and reagents these findings were confirmed 
(Figure  2). The N Latex FLC assays demonstrated a high 
lot-to-lot consistency, which allows for flexible calibration 
by combining different lots of latex reagents, supplemen-
tary reagent, standard and controls.
Good precision over the whole measuring range is 
of importance for calculation of the involved/uninvolved 
FLC ratio to accurately predict progression of smoulding 
multiple myeloma patients to active malignant disease 
[12]. The N Latex FLC assays showed good precision 
with  %CVs  < 5%–7% over the whole measuring range, 
whereas Freelite® assays may have higher imprecision of 
up to 40% at very low concentrations [5, 10], probably 
due to dilution anomalies, that is, the so-called ‘FLC gap 
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Figure 1: Parallel measurement of 2155 routine serum samples with the Freelite® (A) and the N Latex (B) κFLC and λFLC assays and the 
κFLC/λFLC ratio comparison between the methods (C).
In Figure A and B, the dotted horizontal and vertical lines indicate the reference ranges for the assays and the diagonal lines indicates the 
area with normal κFLC/λFLC ratios. In Figure C, the diagonal line indicates y = x. In this figure 144 samples are not included because either 
ratio was designed zero by the technician.
effect’ [2]. The N Latex FLC assays do no suffer from the 
‘gap effect’.
The N Latex FLC assays show good linearity for κ and 
λFLC within the initial measuring dilution, but also for 
clinical samples with concentrations of κ and λFLC far 
above this range [5, 10, 13].
The N Latex FLC applications on the BN™ systems 
have built-in pre-reaction protocols to secure antigen 
excess protection. This protocol is highly effective for both 
κ and λFLC. However, certain monoclonal FLC samples 
show a non-linear dilution behavior, the result in the next 
dilution providing a higher result than expected [10, 14]. 
Jacobs et al. [14] studied the effect of sample dilution on 
recovery by N Latex FLC and Freelite® assays, and similar 
to the study by Vercammen et  al. using Freelite® [15], 
showed that the detection of especially κFLC is signifi-
cantly hindered by the presence of high concentrations of 
M-proteins [14, 15]. The detection of FLC in healthy donors 
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Figure 2: Lot to lot consistency of the N Latex κFLC (A) and λFLC (B) 
assays.
From: Ref. [5].
with at least 500-fold molar excess of bound LCs to heavy 
chains in immunoglobulins compared to free, unbound, 
LC gives no interference. When there is a high concentra-
tion of monoclonal intact immunoglobulin present, the 
ratio of bound versus FLC shifts to even higher numbers 
and the ratio bound versus free may easily exceed 5000-
fold excess. There is always a chance that part of the 
monoclonal intact immunoglobulin is not correctly folded 
and part of the bound LC is exposed. If one epitope is 
exposed, part of the reagent is blocked by this bound LC, 
which results in false-low FLC concentrations in the initial 
dilution of the assay. The exposed epitope thus interferes 
with the reaction. The true concentration can only be 
given at higher dilutions of the samples. This interference 
is patient, that is, sample, specific and found with both 
Freelite® and N Latex FLC assays [14].
VanDuijn et al. described a new mass spectrometry 
(MS) analysis of the light chains in serum [16]. The corre-
lations between the MS method, N Latex FLC assays and 
Freelite® were very good, but the MS method requires 
intensive processing before analysis because all bound 
LCs in intact immunoglobulins need to be discarded. 
The MS method also revealed gross overestimation by 
Freelite® measured on the Siemens BNII and some over-
estimation by the N Latex FLC. The difference between 
Freelite® and N Latex FLC in this context is remarkable, 
because the concentrations of the calibrators for the N 
Latex FLC are derived from one single lot of the Freelite® 
assays.
For the calibration of the N Latex FLC assays, the first 
master calibrator was made in 2008 in the same formu-
lation as the calibrator and controls of the kit and stored 
at –80 °C. In 2008, this master calibrator was calibrated 
to the one lot of Freelite® assays. Due to the significant 
variability of Freelite® kits [17], the in-house master cali-
brator showed unacceptable high variability when meas-
ured on successive lots of Freelite®. All working standards 
are derived from this one-time calibrated lot of master 
calibrator.
The master calibrator is controlled each year for drift 
by measuring fresh samples from 200 donors from the 
blood bank population. The samples come from the same 
donor population that was used to establish reference 
ranges for these assays.
ANOVA gauge repeatability and reproducibility meas-
urements were performed to determine the total amount 
of variability of the BN™ system itself. They were com-
pared to the variability of the FLC measurement itself. The 
measurements were performed on 3 BN™ systems with 
1130 κFLC and 920 λFLC results. The variation for κFLC 
was 4.4% and for λFLC was 3.1% (unpublished data).
Reference intervals were created with 253 EDTA 
plasma samples and 114 serum samples from normal 
healthy blood bank donors aged 18–70 years: κFLC 6.7–
22.4 mg/L, λFLC 8.3–27 mg/L and FLC ratio 0.31–1.56 [5]. 
Jacobs et  al. and Tate et  al. studied patients with renal 
impairment with chronic kidney disease (CKD) class 1–5 
[18, 19]. As κ and λFLC increased significantly but pro-
portionally with every CKD increment, the N Latex FLC 
does not need special reference ranges for the FLC ratio in 
patients with renal impairment.
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Assay performance in disease
The international guidelines indicate that the measure-
ments of FLC should be combined with a clinical history 
and other diagnostic tests to reach high clinical sensi-
tivity and specificity for different disease states [12, 17]. 
Just like the Freelite® assays, the N Latex FLC assays 
show diagnostic and clinical limitations partly due to the 
nature of the FLC proteins which may lead to reduced rec-
ognition [11, 20–22] Therefore FLC assays should be used 
in conjunction with other laboratory tests [13, 20]. In the 
diagnosis of AL amyloidosis, when the FLC measurement 
is combined with serum and urine protein electrophore-
sis and immunofixation (IFE) the diagnostic sensitivity, 
that is, the identification of the amyloidogenic clone, is 
reported to be 98% for both N Latex and Freelite® assays 
[23, 24].
When used in daily practice, the correlation and con-
cordance rate for screening of patients with plasma cell 
dyscrasias between Freelite®, serum-IFE and N Latex FLC 
was good [8, 11, 13, 16, 21, 22, 25]. Although the studies 
were performed with limited numbers of patients, the N 
Latex FLC showed 97%–100% clinical specificity (true 
negative) and 60%–65% sensitivity (true positive), com-
pared to 94%–97% and 61%–72% for Freelite®, respec-
tively, when compared to serum-IFE [21, 22].
The guidelines for monitoring disease states are 
based on the Freelite® assays on the Siemens BNII system 
[17]. Numerical differences in the FLC ratio between the 
assays, partly due to the ‘gap effect’ in the Freelite® assays 
and to differences in λFLC concentration between N Latex 
and Freelite® assays mean that guideline response crite-
ria based on Freelite® assays may not fully apply to the 
N Latex FLC assays [10, 17, 26–33]. However, N Latex FLC 
can accurately be used for prognostic stratification in AL 
amyloidosis patients based on the guidelines by Comenzo 
et al., as demonstrated by Mollee et al. and Palladini et al. 
[23, 24, 34]. The survival rate according to a revised staging 
system can be predicted in these patients, but the response 
assessment needs to be further evaluated in larger studies 
[23, 24]. N Latex FLC is fairly new to the market and not all 
diseases have been specifically studied with these assays. 
More studies are needed to demonstrate the clinical per-
formance of the tests.
The Seralite® dual κ and λ assay
Seralite® (Abingdon Health, York, UK) is a rapid and port-
able diagnostic device enabling the simultaneous quan-
titative measurement of serum κ and λFLC. Seralite® 
generates FLC results in a rapid timeframe and is designed 
to accelerate clinical decision-making near the patient. 
Using highly-specific and extensively validated mouse 
anti-human κ and anti-human λ mAbs [2], Seralite® is the 
first available FLC immunoassay to use a competitive inhi-
bition format to prevent against false negatives caused by 
antigen-excess, a feature of non-competitive FLC assays 
that arises as a result of high FLC levels in patients with 
plasma cell dyscrasias.
Assay principle
Serum is mixed gently with sample application buffer 
provided with the Seralite® kit. As illustrated in Figure 3, 
an aliquot is then added to the Seralite® device, where 
it initially flows through a sample pad, and then onto 
a conjugate release pad containing gold-nanoparticle 
labeled anti-κ and anti-λ mAbs. These mAbs rehydrate, 
and together with the diluted sample, flow across a test 
membrane. At the end of the test membrane are two test 
lines, which contain purified κFLC or λFLC. The flow of 
sample and gold-labeled mAbs is allowed to continue for 
10 min during which time any FLC in the sample will bind 
to its respective gold-labeled mAb; the higher the concen-
tration of FLC in the sample, the less gold-labeled mAb 
will bind to the test line, and vice versa. The line inten-
sity of the binding is determined by the Seralite® reader 
which also times the incubation, calculates the concen-
tration of FLCs in the sample (from a stored calibration 
curve) and calculates the FLC ratio. The Seralite® initial 
calibration curve for κ and λFLC is 2.5–200 mg/L. If the 
FLC level in a sample is above 200 mg/L, a further sample 
dilution of one in 20 extends the upper range of the assay 
to 4000 mg/L This broad Seralite® calibration range, com-
bined with the elimination of antigen excess, reduces 
the need for frequent sample dilution and is designed to 
improve laboratory workflow. The calibrators used for 
Seralite® are traceable to an original calibrator, which was 
tested on multiple batches of Freelite®, as there is no rec-
ognized international standard for FLC.
FLC antibody specificity
Over the past 20  years or so, numerous attempts have 
been made to generate anti-FLC mAbs that may be suit-
able for use in FLC immunoassays [3–5, 35]. To be effi-
cacious, anti-FLC mAbs must identify epitopes that 
are exposed on FLC but hidden on LCs bound to heavy 
chains; thus eliminating mAb cross-reactivity with whole 
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immunoglobulin, a feature of polyclonal antibody based 
assays [35]. Crucially, the mAbs must detect each unique 
FLC secreted from a diverse range of plasma cells from 
all patients. This mission is made more difficult by the 
limited number of constant domain epitopes available on 
FLCs, and by the polymerisation of FLCs, particularly λ, 
which thus reduces the availability of mAb binding sites. 
As of yet, suitable mAbs that meet these criteria have not 
been met as these mAbs either: failed to identify monoclo-
nal FLCs in patient samples, or were not validated against 
thousands of samples containing a wide variety of differ-
ent monoclonal proteins [35, 36].
Seralite® utilizes anti-FLC mAbs which have been 
extensively validated against thousands of patient 
samples, firstly in a multi-plex bead array assay [2], and 
more recently in Seralite®. Initially, the mAbs were shown 
to successfully detect monoclonal FLC – where present 
and identifiable by the gold standard of urine-IFE, in 
13,090 consecutive urine samples. The mAbs also iden-
tified monoclonal FLC in serum from 1000 consecutive 
clinical samples. Half of these 1000 samples contained 
monoclonal FLC, detected in paired urine samples by IFE, 
and it was found that the mAbs identified an abnormal 
FLC ratio in all of these samples and showed excellent 
diagnostic concordance with course of disease assessed 
by other laboratory tests of disease activity and clinical 
course documented in myeloma trial databases. Further-
more, the assay correlated excellently with Freelite® for 
the quantitation of normal polyclonal FLC in serum from 
healthy donors. Thus, the mAbs appear to be at least close 
to the ideal of detecting FLC from all plasma cell clones in 
all patients [2].
Analytical performance
The analytical performance of Seralite® is in submission 
in a separate publication and representative data is pre-
sented herein as an illustration of assay performance. Total 
imprecision has been assessed by the analysis of samples 
containing a range of FLC concentrations (5–74 mg/L). 
These were tested, as per the directions provided in the 
test kit, by three operators, on two Seralite® readers, using 
two different batches of test kits, on a total of 60 devices. 
There were no significant differences between readers, 
operators or kit lots and percentage CVs were between 9% 
and 12%. No significant interference was observed upon 
assessment of common interference agents, including 
cholesterol, triglyceride, bilirubin and hemoglobin added 
at final concentrations of 5.2, 11.3 mmol/L, 342 μmol/L and 
2 g/L, respectively to samples with normal and elevated 
FLC levels. Together, these findings replicated Seralite® 
mAb performance in a prior report [2]. High levels of FLC 
in serum from patients with plasma cell dyscrasias have 
been shown to result in lower than expected FLC levels; 
a result of ‘antigen excess’ that affects direct turbidimet-
ric and nephelometric immunoassays which also gives 
rise to non-linear dilutions [29, 32]. To prevent against 
Figure 3: Schematic view of a single Seralite® device.
Refer to text for assay principle.
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antigen excess, Seralite® utilizes a competitive inhibition 
format, which means that as FLC levels increase, available 
binding sites on the gold-labeled mAb become saturated 
and the mAb is inhibited from binding to the immobilized 
FLC antigen on the membrane; a false negative due to 
antigen excess is thus not possible [37]. To demonstrate 
elimination of antigen excess on Seralite®, Table 1 illus-
trates a number of case studies whereby antigen excess 
was evident on Freelite®, but not on Seralite®. Given the 
broad extremes exhibited by FLCs in the general popu-
lation – ranging from below 1–2 mg/L in immune sup-
pression to over 10 g/L in multiple myeloma – this is an 
important technical development that will ensure protec-
tion against antigen excess.
Assay performance in disease
Seralite® correlates with Freelite® in samples from healthy 
donors (Figure 4A–C), (unpublished data) where both 
assays exhibit similar quantitation of absolute poly-
clonal κ and λFLC, and FLC ratio. The results are signifi-
cantly correlated (κFLC, p < 0.001; λFLC, p < 0.001; FLC 
ratio, p = 0.007). Unlike Freelite®, Seralite® satisfactorily 
identifies FLC in patients with low levels of uninvolved 
FLC (Figure 4, panels D and E), and does not exhibit the 
‘gaps’ between ~2 mg/L and ~7 mg/L that are seen in the 
lower end of the Freelite® assay range [2]. This feature of 
Freelite® must be taken into account when monitoring 
patients with plasma cell dyscrasias; an ‘artefactual’ shift 
from 7 mg/L to 1 mg/L in uninvolved Freelite® FLC level 
will cause an ‘artefactual’ seven-fold change in FLC ratio. 
Illustrated in the panel D and E of Figure 4 are uninvolved 
FLC in 247 myeloma patients at disease presentation; the 
Freelite® ‘gaps’ below 7 mg/L are clearly identifiable. In 
clinical practice, the FLC difference (involved FLC minus 
uninvolved FLC) is used to monitor response to therapy 
and monitor for relapse. Illustrated in panel F of Figure 4 is 
the FLC difference calculated for 114 patients at myeloma 
presentation; all patients presented with a FLC parapro-
tein visible in serum-IFE or in a paired urine sample by 
IFE. It can be seen that Seralite® and Freelite® exhibited 
diagnostic concordance, but quantitative estimation of 
monoclonal FLCs from neoplastic plasma cells was often 
divergent. Thus, in order to compare FLC levels between 
two samples from the same patient, it is important that 
same assay method is used; as is the case for monitoring 
whole paraprotein levels.
In a separate study, larger cohorts of myeloma patients 
(n = 476) with light chain only myeloma, non-secretory 
myeloma, and intact immunoglobulin myeloma (IgA, 
IgG, IgD) were monitored through disease presentation, 
response to therapy, remission and relapse [38]. Seralite® 
provided excellent diagnostic concordance with Freelite® 
in these patient groups [38]. Seralite® clinical validation 
was extended to assess serial serum FLC measurements in 
patients who presented with IgA or IgG myeloma, who devel-
oped a relapse characterized by an increase in FLC (Δ > 100 
mg/L and  > 25%) without a corresponding increase in the 
heavy chain level, a phenomenon termed serum FLC escape 
(LCE escape) [39]. Seralite® identified an increase in the 
involved FLC and abnormal FLC ratio in all of these patients 
at LCE escape, and again demonstrated excellent diagnostic 
concordance with the Freelite® assay for κ and λFLC levels 
[39]. The clinical utility of Seralite® has also been demon-
strated for diagnosing myeloma kidney in 288 patients with 
acute kidney injury (biopsy confirmed and all glomerular 
filtration rates  < 15 mL/min). Seventy-eight of these patients 
had a confirmed myeloma diagnosis and all were identified 
as having elevated involved FLC and an abnormal FLC ratio 
on Seralite®; Seralite® had excellent diagnostic concordance 
with Freelite® in all serum samples tested [40].
Taken together, these retrospective studies dem-
onstrate that Seralite® is effective in diagnosing and 
Table 1: Results from five samples that had antigen excess with Freelite® assay.
Sample
 
 
Freelite®, mg/L  
 
Seralite®, mg/L  
 
Freelite®, mg/L  
 
Seralite®, mg/L
κ (initial 
dilution)
  κ (final 
result)
κ (initial 
dilution)
  κ (final 
result)
λ (initial 
dilution)
  λ (final 
result)
λ (initial 
dilution)
  λ (final 
result)
A   0.77   664.00   78.8   78.8   6.35   6.35    < 2.5    < 2.5
B   6.51   6.51    < 2.5    < 2.5   15.63   1772.00    > 200   39,480.00
C   22.09   5435.00    > 200   4960.00   10.77   10.77   6.7   6.7
D   37.64   31,594.00    > 200   22,320.00   8.66   8.66   3.4   3.4
E   1.3   14,723    > 200   32,160   5.34   0.85    < 2.5    < 2.5
Initial results with Seralite® and Freelite® assays are shown. Samples were then diluted at a higher dilution as recommended with the 
 Freelite® assay when antigen excess is suspected.
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Figure 4: Comparison between Seralite® and Freelite® assays.
Plots A, B and C show comparative data for κFLC, λFLC and FLC ratio in healthy donors (n = 144). Plot D illustrates uninvolved κFLC in myeloma 
patients with a λ paraprotein (n = 109). Plot E illustrates uninvolved λFLC in myeloma patients with a κ paraprotein (n = 138). Plot F shows 
comparative results for FLC difference (involved minus uninvolved), in 114 myeloma patients at diagnosis; 67 patients had κFLC in serum-IFE, 
and 47 patients had λFLC in serum-IFE. Dotted lines represent Freelite reference range for normal healthy donors.
monitoring plasma cell dyscrasias. The aforementioned 
studies have been presented at recent hematology meet-
ings and, are in submission for publication elsewhere. 
Future independent studies will address the prospec-
tive utility of Seralite® in clinical practice. In conclusion, 
Seralite® is a rapid and portable diagnostic device that 
facilitates near-patient quantitation of FLC in serum. 
Using highly-specific and extensively validated anti-κ and 
anti-λ mAbs [2], Seralite® is designed to accelerate clini-
cal decision-making and is the first available FLC immu-
noassay to use a competitive inhibition format to prevent 
against antigen-excess. Generation of rapid FLC results 
may empower clinicians to establish disease status and 
make informed treatment decisions more quickly and 
efficiently.
Conclusions
FLC measurements play a pivotal role in the screening, mon-
itoring and prediction of progression of disease for patients 
with plasma cell dyscrasias. The great number of publica-
tions on FLC measurements demonstrates that patient 
management greatly benefits from the use of FLC assays. 
The introduction of the monoclonal-based FLC assays has 
opened new perspectives for the clinical laboratory and 
allows rapid testing in the clinic. It has demonstrated the 
analytical pro- and cons of the old and the new assays, but 
it also highlighted that the monoclonal κ and λLC proteins 
come in many forms and the same FLC may be measured at 
different concentrations depending on the assay. Although 
the correlations and concordance between the assays are 
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good between the polyclonal and monoclonal-based FLC 
assays, the results are not interchangeable, as is well estab-
lished for different methods to detect whole M-proteins. 
Indeed, during the development of the Seralite® assays, it 
became apparent that the measured concentrations of FLC 
in serum depend on the antibodies used for the assays [2]. 
Crucially, however, the monoclonal-based assays herein 
provide similar reaction patterns to the polyclonal-based 
assays, and high levels of involved monoclonal FLC are 
identified at disease presentation, show a reduction during 
successful disease therapy, and an increase at disease pro-
gression. Thus, an adequate period of parallel testing should 
enable the continued accurate follow up of the patient if 
changing from one test method to another. Benefits of using 
mAbs assays include that users evade lot-to-lot variations as 
seen – even with successive batches of polyclonal antibod-
ies – on Freelite®. Indeed, within the collection of Freelite® 
assays, customers notice differences in outcome in EQAS 
studies when the assays are performed on different systems 
[20]. This shows that – in a similar manner to whole M-pro-
tein assays – results for different FLC assays on different 
clinical analyzers are not interchangeable. At the same time, 
the differences between the methods demonstrate how dif-
ficult standardization of the FLC assays will be.
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